Executives plan to build on shared technologiesLong-time allies Emageon and UltraVisual have merged. Emageon had specialized in medical image storage, distribution, and workflow solutions. UltraVisual of Madison, WI, had focused on
Executives plan to build on shared technologies
Long-time allies Emageon and UltraVisual have merged. Emageon had specialized in medical image storage, distribution, and workflow solutions. UltraVisual of Madison, WI, had focused on the development of enterprise-wide medical image visualization software. Shareholders of the two companies approved the merger, effective May 30. Company headquarters will be in Birmingham, AL, where Emageon had been based. Visualization software development will continue in Madison.
"Unlike many mergers that predict or hope for product synergies, the merger of Emageon and UltraVisual is based on actual, proven synergies already in place with customers," said Chuck Jett, Emageon CEO and chairman.
Mark Gehring, UltraVisual's cofounder, CEO, and chairman, described the merger as having been clinically "road tested," in that technology from both companies is already in widespread use. The two companies have signed 18 hospitals to projects involving shared technologies in just the last half-year, he said.
Both committed early to DICOM, HL7, and IHE standards yet maintained their hardware independence. The merged open platforms should create further value for customers by supporting seamless integration to high-end specialty and disease-specific applications, according to Emageon COO Milton Silva-Craig.
"Each company has emphasized meeting industry demands," he said. "Our combined solution enhances our ability to improve the quality of care that can be delivered by improving service to referring physicians."
Together, the two newly merged companies offer an integrated solution of technology and services, Gehring said. Moreover, both share a common vision for the development of their technologies and implementation of services.
"Our merger with Emageon leverages the technical strengths of both companies," he said.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.